• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun Vulnerabilities in Coronavirus Glycan Shields Despite Extensive Glycosylation

tetano

Editor, Senior Moderator
Nat Commun


. 2020 May 27;11(1):2688.
doi: 10.1038/s41467-020-16567-0.
Vulnerabilities in Coronavirus Glycan Shields Despite Extensive Glycosylation


Yasunori Watanabe[SUP] 1 2 3 [/SUP], Zachary T Berndsen[SUP] 4 [/SUP], Jayna Raghwani[SUP] 5 [/SUP], Gemma E Seabright[SUP] 1 2 [/SUP], Joel D Allen[SUP] 1 [/SUP], Oliver G Pybus[SUP] 6 [/SUP], Jason S McLellan[SUP] 7 [/SUP], Ian A Wilson[SUP] 4 8 [/SUP], Thomas A Bowden[SUP] 3 [/SUP], Andrew B Ward[SUP] 4 [/SUP], Max Crispin[SUP] 9 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66-87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface.
 
Back
Top